UNSPSC 51241122: Pegaptanib

This classification denotes an angiogenesis inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H1PA8H1EN. European Medicines Agency schedules Pegaptanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25196. Pegaptanib generally arises in the molecular formula C15H28N3O6(C2H4O)N(C2H4O)N. The term PEGAPTANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, no. 2, 2003, list 49.) Most nations schedule pegaptanib under HS 39072021 and SITC 57419.

As of Q4 2014, PEGAPTANIB remains the US FDA Preferred Term for this commodity. Pegaptanib bears US NLM identifiers UMLS ID C1531015 and NCI Concept Code C90657. SMILES: COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC.

UNSPSC 51241122 Pegaptanib is a Commodity code for a specific therapeutic pharmaceutical — an anti-vascular endothelial growth factor (anti-VEGF) agent administered by intravitreal injection to treat age-related macular degeneration (AMD) and other retinal conditions. State and local procurement activity under this code centers on acquiring the drug itself for use in public health systems, hospital networks, and clinics operated or funded by government entities. The issuing bodies soliciting under this code are typically state health departments, county health authorities, public hospital systems, and integrated health networks that operate ophthalmology or retina services.

The source contains no recent state or local contract opportunities posted under UNSPSC 51241122. Without posted opportunities, the geographic spread and current procurement intensity cannot be determined from the available record. Firms pursuing this code should monitor state Medicaid procurement channels, public hospital system RFPs, and health department cooperative purchasing vehicles, as pharmaceutical acquisitions for specialty care often move through those channels rather than appearing as standalone contract notices.